Literature DB >> 25158255

Modulation of expressivity in PDGFRB-related infantile myofibromatosis: a role for PTPRG?

N D Linhares1, M C M Freire2, R G C C L Cardenas1, M Bahia3, E Puzenat4, F Aubin4, S D J Pena5.   

Abstract

Infantile myofibromatosis is a rare genetic disorder characterized by the development of benign tumors in the skin, muscle, bone, and viscera. The molecular pathogenesis is still incompletely known. An autosomal dominant form had been reported as causally related with mutations in the gene for platelet-derived growth factor receptor beta (PDGFRB). We report here two siblings with infantile myofibromatosis and with a PDGFRB mutation identified by exome sequence analysis. However, the unaffected mother also had the same PDGFRB mutation. We showed that both children had also inherited from their healthy father a heterozygous mutation in the gene for receptor protein tyrosine phosphatase gamma (PTPRG), an enzyme known to dephosphorylate PDGFRB. We suggest that in this family, the additional mutation in PTPRG may explain the full phenotypic penetrance in the siblings affected, in comparison with the unaffected mother.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25158255     DOI: 10.4238/2014.August.15.11

Source DB:  PubMed          Journal:  Genet Mol Res        ISSN: 1676-5680


  7 in total

Review 1.  PDGF receptor mutations in human diseases.

Authors:  Emilie Guérit; Florence Arts; Guillaume Dachy; Boutaina Boulouadnine; Jean-Baptiste Demoulin
Journal:  Cell Mol Life Sci       Date:  2021-01-15       Impact factor: 9.261

2.  PDGFRB mutants found in patients with familial infantile myofibromatosis or overgrowth syndrome are oncogenic and sensitive to imatinib.

Authors:  F A Arts; D Chand; C Pecquet; A I Velghe; S Constantinescu; B Hallberg; J-B Demoulin
Journal:  Oncogene       Date:  2015-10-12       Impact factor: 9.867

3.  Novel PDGFRB rearrangement in multifocal infantile myofibromatosis is tumorigenic and sensitive to imatinib.

Authors:  Mohammed Hassan; Erin Butler; Raphael Wilson; Angshumoy Roy; Yanbin Zheng; Priscilla Liem; Dinesh Rakheja; Dean Pavlick; Lauren L Young; Mark Rosenzweig; Rachel Erlich; Siraj M Ali; Patrick J Leavey; D Williams Parsons; Stephen X Skapek; Theodore W Laetsch
Journal:  Cold Spring Harb Mol Case Stud       Date:  2019-10-23

4.  A patient with germ-line gain-of-function PDGFRB p.N666H mutation and marked clinical response to imatinib.

Authors:  Dinel Pond; Florence A Arts; Nancy J Mendelsohn; Jean-Baptiste Demoulin; Gunter Scharer; Yoav Messinger
Journal:  Genet Med       Date:  2017-07-20       Impact factor: 8.822

5.  Aggressive infantile myofibromatosis with intestinal involvement.

Authors:  Tristan Römer; Norbert Wagner; Till Braunschweig; Robert Meyer; Miriam Elbracht; Udo Kontny; Olga Moser
Journal:  Mol Cell Pediatr       Date:  2021-06-16

6.  Effects of Sunitinib and Other Kinase Inhibitors on Cells Harboring a PDGFRB Mutation Associated with Infantile Myofibromatosis.

Authors:  Martin Sramek; Jakub Neradil; Petra Macigova; Peter Mudry; Kristyna Polaskova; Ondrej Slaby; Hana Noskova; Jaroslav Sterba; Renata Veselska
Journal:  Int J Mol Sci       Date:  2018-09-01       Impact factor: 5.923

7.  Genetic testing and surveillance in infantile myofibromatosis: a report from the SIOPE Host Genome Working Group.

Authors:  Simone Hettmer; Guillaume Dachy; Guido Seitz; Abbas Agaimy; Catriona Duncan; Marjolijn Jongmans; Steffen Hirsch; Iris Kventsel; Uwe Kordes; Ronald R de Krijger; Markus Metzler; Orli Michaeli; Karolina Nemes; Anna Poluha; Tim Ripperger; Alexandra Russo; Stephanie Smetsers; Monika Sparber-Sauer; Eveline Stutz; Franck Bourdeaut; Christian P Kratz; Jean-Baptiste Demoulin
Journal:  Fam Cancer       Date:  2020-09-05       Impact factor: 2.375

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.